{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:42:07Z","timestamp":1791996127206,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Actinomycin-D (Act-D) and Methotrexate (MTX) are both effective first-line agents for low-risk gestational trophoblastic neoplasia (LRGTN) with no consensus regarding which is more effective or less toxic. The primary objective of this meta-analysis is to compare Act-D with MTX in the treatment of LRGTN.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically searched electronic databases, conferences abstracts and trial registries for randomized controlled trials (RCTs) and high-quality non-randamized controlled trials (non-RCTs), comparing Act-D with MTX for patients with LRGTN. Studies were full-text screened for quality assessment and data extraction. Eligible studies must have reported complete remission rate. A fixed-effects meta-analysis was conducted to quantify the efficacy and safety of Act-D and MTX on odds ratios (ORs) and 95% confidence intervals (95%CIs), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 8 RCTs and 9 non-RCTs (1674 patients) were included. In terms of efficacy, Act-D is superior to MTX in complete remission (80.2% [551\/687] vs 65.1% [643\/987]; OR 2.15, 95%CI 1.70 to 2.73). In the stratified analysis, patients from RCTs and non-RCTs both had a better complete remission from Act-D-based regimen (RCTs: 81.2% [259\/319] vs 66.1% [199\/301], OR 2.17, 95%CI 1.49 to 3.16; non-RCTs: 79.3% [292\/368] vs 65.0% [444\/686], OR 2.14, 95%CI 1.57 to 2.92). In terms of safety, patients receiving Act-D had higher risks of suffering nausea (OR 2.35, 95%CI 1.68 to 3.27), vomiting (OR 2.40, 95%CI 1.63 to 3.54), and alopecia (OR 2.76, 95%CI 1.60 to 4.75). Notably, liver toxicity (OR 0.38, 95%CI 0.19 to 0.76) was the only one that was conformed to have a higher risk for patients receiving MTX. In addition, the pooled results showed no significant difference of anaemia, leucocytopenia, neutropenia, thrombocytopnia, constipation, diarrhea, anorexia, and fatigue between Act-D and MTX.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our meta-analysis suggests that Act-D had better efficacy profile in general, and MTX had less toxicities in LRGTN. Future clinical trials should be better orchestrated to provide more valid data on efficacy and toxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08849-7","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T23:29:43Z","timestamp":1634599783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies"],"prefix":"10.1186","volume":"21","author":[{"given":"Jiatao","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"7","key":"8849_CR1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1470-2045(07)70204-8","volume":"8","author":"IM Shih","year":"2007","unstructured":"Shih IM. Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets. Lancet Oncol. 2007;8(7):642\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(07)70204-8.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"8849_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0020-7292(03)90120-2","volume":"83","author":"HY Ngan","year":"2003","unstructured":"Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83(Suppl 1):175\u20137. https:\/\/doi.org\/10.1016\/S0020-7292(03)90120-2.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"8849_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajog.2010.06.072","volume":"204","author":"JR Lurain","year":"2011","unstructured":"Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2010.06.072.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"8849_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ygyno.2012.03.039","volume":"125","author":"E Chapman-Davis","year":"2012","unstructured":"Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol. 2012;125(3):572\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2012.03.039.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8849_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ygyno.2008.09.005","volume":"112","author":"RS Berkowitz","year":"2009","unstructured":"Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112(3):654\u201362. https:\/\/doi.org\/10.1016\/j.ygyno.2008.09.005.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"8849_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","volume":"29","author":"RJ Osborne","year":"2011","unstructured":"Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;29(7):825\u201331. https:\/\/doi.org\/10.1200\/JCO.2010.30.4386.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8849_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3181\/00379727-93-22757","volume":"93","author":"R Hertz","year":"1956","unstructured":"Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93(2):361\u20136. https:\/\/doi.org\/10.3181\/00379727-93-22757.","journal-title":"Proc Soc Exp Biol Med"},{"key":"8849_CR8","first-page":"1015","volume":"22","author":"GT Ross","year":"1962","unstructured":"Ross GT, Stolbach LL, Hertz R. Actinomycin D in the treatment of methotrexate-resistant trophoblastic disease in women. Cancer Res. 1962;22:1015\u20137.","journal-title":"Cancer Res"},{"issue":"6","key":"8849_CR9","first-page":"CD007102","volume":"2016","author":"TA Lawrie","year":"2016","unstructured":"Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;2016(6):CD007102.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8849_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ygyno.2017.11.031","volume":"148","author":"J Li","year":"2018","unstructured":"Li J, Li S, Yu H, Wang J, Xu C, Lu X. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: a network meta-analysis. Gynecol Oncol. 2018;148(2):247\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2017.11.031.","journal-title":"Gynecol Oncol"},{"issue":"jul21 1","key":"8849_CR11","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(jul21 1):b2700. https:\/\/doi.org\/10.1136\/bmj.b2700.","journal-title":"BMJ"},{"key":"8849_CR12","first-page":"ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"8849_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4.","journal-title":"Control Clin Trials"},{"issue":"3","key":"8849_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/SLA.0b013e31824682f4","volume":"255","author":"EF Vi\u00f1uela","year":"2012","unstructured":"Vi\u00f1uela EF, Gonen M, Brennan MF, Coit DG, Strong VE. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg. 2012;255(3):446\u201356. https:\/\/doi.org\/10.1097\/SLA.0b013e31824682f4.","journal-title":"Ann Surg"},{"issue":"9","key":"8849_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"issue":"2","key":"8849_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12.","journal-title":"Res Synth Methods"},{"issue":"4","key":"8849_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101. https:\/\/doi.org\/10.2307\/2533446.","journal-title":"Biometrics"},{"issue":"7109","key":"8849_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"1","key":"8849_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000500165","volume":"64","author":"HL Kang","year":"2019","unstructured":"Kang HL, Zhao Q, Yang SL, Duan W. Efficacy of combination therapy with Actinomycin D and methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Chemotherapy. 2019;64(1):42\u20137. https:\/\/doi.org\/10.1159\/000500165.","journal-title":"Chemotherapy"},{"issue":"5","key":"8849_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/IGC.0000000000000687","volume":"26","author":"F Yarandi","year":"2016","unstructured":"Yarandi F, Mousavi A, Abbaslu F, Aminimoghaddam S, Nekuie S, Adabi K, et al. Five-day intravascular methotrexate versus biweekly Actinomycin-D in the treatment of low-risk gestational trophoblastic neoplasia: a clinical randomized trial. Int J Gynecol Cancer. 2016;26(5):971\u20136. https:\/\/doi.org\/10.1097\/IGC.0000000000000687.","journal-title":"Int J Gynecol Cancer"},{"key":"8849_CR21","first-page":"78","volume":"28","author":"N Shahbazian","year":"2014","unstructured":"Shahbazian N, Razi T, Razi S, Yazdanpanah L. Comparison of the efficacy of methotrexate and actinomycin D in the treatment of patients with stage I low risk gestational trophoblastic neoplasia (GTN). Med J Islam Repub Iran. 2014;28:78.","journal-title":"Med J Islam Repub Iran"},{"issue":"1","key":"8849_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijgo.2011.08.003","volume":"116","author":"A Mousavi","year":"2012","unstructured":"Mousavi A, Cheraghi F, Yarandi F, Gilani MM, Shojaei H. Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease. Int J Gynaecol Obstet. 2012;116(1):39\u201342. https:\/\/doi.org\/10.1016\/j.ijgo.2011.08.003.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"8849_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/IGC.0b013e3181a8333d","volume":"19","author":"AA Lertkhachonsuk","year":"2009","unstructured":"Lertkhachonsuk AA, Israngura N, Wilailak S, Tangtrakul S. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer. 2009;19(5):985\u20138. https:\/\/doi.org\/10.1111\/IGC.0b013e3181a8333d.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"8849_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1479-828X.2005.00366.x","volume":"45","author":"MM Gilani","year":"2005","unstructured":"Gilani MM, Yarandi F, Eftekhar Z, Hanjani P. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol. 2005;45(2):161\u20134. https:\/\/doi.org\/10.1111\/j.1479-828X.2005.00366.x.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"2","key":"8849_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ygyno.2020.05.013","volume":"158","author":"JC Schink","year":"2020","unstructured":"Schink JC, Filiaci V, Huang HQ, Tidy J, Winter M, Carter J, et al. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG\/GOG 275. Gynecol Oncol. 2020;158(2):354\u201360. https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.013.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"8849_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ajo.12622","volume":"57","author":"L Verhoef","year":"2017","unstructured":"Verhoef L, Baartz D, Morrison S, Sanday K, Garrett AJ. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland trophoblast Centre (QTC). Aust N Z J Obstet Gynaecol. 2017;57(4):458\u201363. https:\/\/doi.org\/10.1111\/ajo.12622.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"5","key":"8849_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12094-014-1251-1","volume":"17","author":"H Al-Husaini","year":"2015","unstructured":"Al-Husaini H, Soudy H, Darwish A, Ahmed M, Eltigani A, Edesa W, et al. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience. Clin Transl Oncol. 2015;17(5):409\u201315. https:\/\/doi.org\/10.1007\/s12094-014-1251-1.","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"8849_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1590\/SO100-720320150005366","volume":"37","author":"EM Uberti","year":"2015","unstructured":"Uberti EM, Fajardo Mdo C, da Cunha AG, Frota SS, Braga A, Ayub AC. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women. Rev Bras Ginecol Obstet. 2015;37(6):258\u201365. https:\/\/doi.org\/10.1590\/SO100-720320150005366.","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"8849_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ygyno.2007.09.006","volume":"108","author":"RA Abr\u00e3o","year":"2008","unstructured":"Abr\u00e3o RA, de Andrade JM, Tiezzi DG, Marana HR. Candido dos reis FJ, Clagnan WS. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecol Oncol. 2008;108(1):149\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2007.09.006.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8849_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijgo.2008.05.013","volume":"103","author":"F Yarandi","year":"2008","unstructured":"Yarandi F, Eftekhar Z, Shojaei H, Kanani S, Sharifi A, Hanjani P. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2008;103(1):33\u20137. https:\/\/doi.org\/10.1016\/j.ijgo.2008.05.013.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"8849_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijgo.2012.04.027","volume":"119","author":"AM Baptista","year":"2012","unstructured":"Baptista AM, Belfort P. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2012;119(1):35\u20138. https:\/\/doi.org\/10.1016\/j.ijgo.2012.04.027.","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"8849_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ygyno.2004.11.011","volume":"96","author":"H Matsui","year":"2005","unstructured":"Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol. 2005;96(3):616\u201320. https:\/\/doi.org\/10.1016\/j.ygyno.2004.11.011.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"8849_CR33","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.3802\/jgo.2017.28.e8","volume":"28","author":"YJ Lee","year":"2017","unstructured":"Lee YJ, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease. J Gynecol Oncol. 2017;28(2):e8. https:\/\/doi.org\/10.3802\/jgo.2017.28.e8.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"8849_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000009987","volume":"46","author":"H Matsui","year":"1998","unstructured":"Matsui H, Iitsuka Y, Seki K, Sekiya S. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecol Obstet Investig. 1998;46(1):5\u20138. https:\/\/doi.org\/10.1159\/000009987.","journal-title":"Gynecol Obstet Investig"},{"issue":"11","key":"8849_CR35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S1470-2045(03)01245-2","volume":"4","author":"A Altieri","year":"2003","unstructured":"Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4(11):670\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(03)01245-2.","journal-title":"Lancet Oncol"},{"issue":"3","key":"8849_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00254018","volume":"4","author":"RA Grimm","year":"1980","unstructured":"Grimm RA, Muss HB, White DR, Richards F 2nd, Cooper MR, Stuart JJ, et al. Actinomycin D in the treatment of advanced breast cancer. Cancer Chemother Pharmacol. 1980;4(3):195\u20137. https:\/\/doi.org\/10.1007\/BF00254018.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"8849_CR37","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/1097-0142(197509)36:3<863::AID-CNCR2820360306>3.0.CO;2-G","volume":"36","author":"R Osathanondh","year":"1975","unstructured":"Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer. 1975;36(3):863\u20136. https:\/\/doi.org\/10.1002\/1097-0142(197509)36:3<863::AID-CNCR2820360306>3.0.CO;2-G.","journal-title":"Cancer."},{"issue":"1","key":"8849_CR38","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1016\/S1470-2045(17)30686-1","volume":"19","author":"J Ireson","year":"2018","unstructured":"Ireson J, Jones G, Winter MC, Radley SC, Hancock BW, Tidy JA. Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach. Lancet Oncol. 2018;19(1):e56\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(17)30686-1.","journal-title":"Lancet Oncol"},{"issue":"2","key":"8849_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1148\/rg.2017160140","volume":"37","author":"AM Shaaban","year":"2017","unstructured":"Shaaban AM, Rezvani M, Haroun RR, Kennedy AM, Elsayes KM, Olpin JD, et al. Gestational trophoblastic disease: clinical and imaging features. Radiographics. 2017;37(2):681\u2013700. https:\/\/doi.org\/10.1148\/rg.2017160140.","journal-title":"Radiographics"},{"issue":"1","key":"8849_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ygyno.2017.10.028","volume":"148","author":"I Maest\u00e1","year":"2018","unstructured":"Maest\u00e1 I, Nitecki R, Horowitz NS, Goldstein DP. de Freitas Segalla Moreira M, Elias KM, et al. effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England trophoblastic disease center experience. Gynecol Oncol. 2018;148(1):161\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2017.10.028.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"8849_CR41","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.1996.14.10.2769","volume":"14","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996;14(10):2769\u201373. https:\/\/doi.org\/10.1200\/JCO.1996.14.10.2769.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08849-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T23:31:06Z","timestamp":1634599866000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08849-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8849"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08849-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is a systematic review and analysis of previously published literatures, ethics is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1122"}}